CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today reported financial results for the second quarter ended June 30, 2007. “We have made solid clinical development and discovery research progress in the first half of 2007. Our lead development program, CRx-102, is well on its way to beginning Phase 2b clinical trials in both osteoarthritis and rheumatoid arthritis in the second half of 2007 as planned,” commented Alexis Borisy, President and CEO of CombinatoRx. “We are also on track to initiate proof-of-concept clinical studies in the second half of 2007 with a number of other promising development programs and have expanded our discovery efforts to include next generation novel combinations including early but compelling in vitro activity in hepatitis C and multiple myeloma.”
